Intrinsiqq
InflaRx N.V. logo

InflaRx N.V. Financials

IFRX

Compare

All currency values in € millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue-€0€0€0€0€0€0
Cost of Revenue€5€7€3€1€0€0
Gross Profit-€5-€7-€3-€0€0€0
Total Operating Expenses€32€41€50€44€32€48
Operating Income-€37-€48-€53-€45-€32-€48
Non-Operating
Net Interest Expense-€0-€0-€0-€0-€0-€0
Income Tax Expense€0€0€0€0€0€0
Net Income
Net Income-€39-€46-€46-€43-€29-€46
Per Share Data
Revenue Per Share-€0.00€0.00€0.00€0.00€0.00€0.00
EPS (Basic)-€0.51-€0.68-€0.78-€0.78-€0.67-€1.10
EPS (Diluted)-€0.51-€0.68-€0.78-€0.78-€0.67-€1.10
Shares Outstanding117.7M67.3M58.9M50.6M42.7M40.2M

InflaRx (IFRX) financials: revenue, profit and margins

InflaRx (IFRX) generated about -€10,101.00 in revenue and -€39 million in net income (a 387,053.7% net margin) over the trailing twelve months, growing at roughly -31.8% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is InflaRx's (IFRX) revenue?+

InflaRx generated about -€10,101.00 in revenue over the trailing twelve months. Revenue has grown at roughly -31.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is InflaRx profitable?+

InflaRx reported about -€39 million in net loss over the trailing twelve months, a net margin of roughly 387,053.7%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are InflaRx's profit margins?+

InflaRx runs a gross margin of about 48,201.6%, an operating margin of about 361,793.1%, a net margin of about 387,053.7%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is InflaRx growing?+

InflaRx's revenue has compounded at roughly -31.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside IFRX's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with IFRX

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing IFRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.